NOT KNOWN FACTUAL STATEMENTS ABOUT SEMAGLUTIDE WEEK 1-6 BUNDLE

The demo realized both of those its Key endpoints, with semaglutide 2.four mg demonstrating statistically significant and excellent enhancements in liver fibrosis without any worsening of steatohepatitis, in addition to resolution of steatohepatitis with no worsening of liver fibrosis in individuals with MASH when compared with placebo.1Notify your